Acute Infectious and Haematological Toxicity in patients with ALL after Consolidation Phase with Methotrexate in the Oncology Center of Javeriana University (2012-2014)
Introduction: Acute lymphocytic leukemia (ALL) is the most common childhood malignancy. Treatment includes 3 phases. During the cosolidation phase the use of methrotexate in different doses, depending on the risk classification, is the treatments main pilar.Objective: To Estimate the presence of feb...
| Autor Principal: | Córdoba Núñez, María Adelaida; Pontificia Universidad Javeriana |
|---|---|
| Otros Autores: | Guzmán Cruz, Paula Carolina; Pontificia Universidad Javeriana, Acero Azuero, Silvia; Pontificia Universidad Javeriana |
| Formato: | info:eu-repo/semantics/article |
| Idioma: | spa |
| Publicado: |
Pontificia Universidad Javeriana
2014
|
| Materias: | |
| Acceso en línea: |
http://revistas.javeriana.edu.co/index.php/vnimedica/article/view/16329 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: |
Introduction: Acute lymphocytic leukemia (ALL) is the most common childhood malignancy. Treatment includes 3 phases. During the cosolidation phase the use of methrotexate in different doses, depending on the risk classification, is the treatments main pilar.Objective: To Estimate the presence of febrile neutropenia, anemia and thrombocytopenia in patients with ALL receiving methotrexate during the consolidation phase at a dose of 5 g/m2 compared to patients who received doses of 2 g/m2.Methods: Review clinical records of all patients between 1 and 15 years old treated for ALL at the Oncology Center of Javeriana University between January 1/2012 and March 10/2014.Results: Information of 66 cycles of chemotherapy were collected, of which 31 corresponded to 2 g/m2 and 35 to 5 g/m2 applications. The frequency of febrile neutropenia in the group 2 g/m2 was 25 % and 34 % in the group 5g/m2, which resembles literature reports.Conclusion: The use of high-dose of methotrexate for the management of ALL in our area did not represent an increase in haematological toxicity compared to low dose group. And there is enough evidence of improved cure rates of the disease. |
|---|